Begin main content


Last Updated: December 14, 2017
Result type: Reports
Project Number: SE0555-000
Product Line: Common Drug Review

Generic Name: Pegfilgrastim

Brand Name: Lapelga

Manufacturer: Apobiologix

Indications: Febrile neutropenia, prevention or treatment

Manufacturer Requested Reimbursement Criteria7: As  the preferred pegfilgrastim product to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

Submission Type: New

Project Status: Pending

Call For Patient Input: December 14, 2017

Patient Input Closed: February 9, 2018

Anticipated Date: January 19, 2018

Biosimilar: Yes

Fee Schedule1: Pending

Submit Feedback